Pandemic (H1N1) 2009 influenza update

Pandemic (H1N1) 2009 influenza update

Issued: Friday 14 August, London UK

GSK today issued an update on its progress to develop a vaccine against the Pandemic (H1N1) 2009 influenza virus, and announced that it has commenced the clinical development programme for its adjuvanted pandemic vaccine. Enrolment into this first study has been completed.

Dr.Thomas Breuer, Head of Global Clinical R&D and Chief Medical Officer of GSK Biologicals, said "GSK is making good progress with the development of its pandemic vaccine.  Enrolment into the first study has been completed and in total, GSK will conduct 16 clinical trials of its pandemic vaccine in over 9000 individuals across Europe, Canada and the US. We continue to work closely with regulators and governments to assess and develop this vaccine."

The first clinical trial, being conducted in Germany, will assess the use of the vaccine in healthy adults. Initial data is expected to be available for sharing with regulatory authorities in September.

Further trials of the Pandemic (H1N1) 2009 adjuvanted vaccine covering infants, children, adults and the elderly will commence over the coming weeks across Europe, Canada and the US. The clinical development programme, which has been designed in close partnership with regulatory authorities, will evaluate the immune response as well as tolerability and other safety aspects of the vaccine.

All the final data on the clinical development programme will be submitted to the regulators as soon as they are available and will be posted on GSK's Clinical Study Register.

About the pandemic (H1N1) 2009 vaccine

The vaccine will comprise antigen of the recently isolated Pandemic (H1N1) 2009 influenza strain and also contain GSK's proprietary adjuvant system AS03.  In clinical studies using the bird flu influenza strain (H5N1), the adjuvanted formulation has been shown to stimulate a higher immune response while using a smaller amount of antigen as compared to a formulation without adjuvant. The vaccine containing the adjuvant system therefore helps to substantially increase the number of vaccine doses that can be provided for mass vaccination.1  In addition, in clinical studies with the bird flu programme, the adjuvanted vaccine demonstrated the potential to provide protection even if the influenza strain drifts (changes slightly).2,3 Both the antigen sparing approach as well as the potential for additional protection against drifting strains are features for an impactful vaccine for use in a pandemic setting.

GSK has received regulatory approvals in the European Union and some Asian countries for its pre-pandemic and pandemic H5N1 vaccines, both of which contain the AS03 adjuvant.  Currently, clinical trials in over 39,000 people have demonstrated that the AS03 adjuvant system used with an influenza vaccine has an acceptable safety and reactogenicity profile.

About the clinical trials

The first clinical trial, being conducted in Germany, has started this week and enrolment has been completed.  The trial will assess the use of the vaccine given as 2 doses, 21 days apart in 128 healthy adults, aged between 18 and 60.  Initial data is expected to be available for submission to regulatory authorities in September.  Additional trials planned in the clinical development programme are expected to commence shortly and include 8 trials in healthy adults, 5 trials in children (including infants) and 2 trials in the elderly. Details of the clinical development programme will be posted to

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit
UK Media enquiries:
 Philip Thomson
 (020) 8047 5502
 David Outhwaite
 (020) 8047 5502
 Stephen Rea
 (020) 8047 5502
 Alexandra Harrison
 (020) 8047 5502
US Media enquiries:
 Nancy Pekarek
 (919) 483 2839
 Mary Anne Rhyne
 (919) 483 2839
 Kevin Colgan
 (919) 483 2839
 Lisa Behrens
 (919) 483 2839
European Analyst/Investor enquiries:
 David Mawdsley
 (020) 8047 5564
 Sally Ferguson
 (020) 8047 5543
 Gary Davies
 (020) 8047 5503
US Analyst/ Investor enquiries:
 Tom Curry
 (215) 751 5419
 Jen Hill Baxter
 (215) 751 7002

Cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk Factors' in the 'Business Review' in the company' s Annual Report on Form 20-F for 2008